Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis
Osteoarthritis (OA) is the most common joint disorder, with a social and financial burden that is expected to increase in the coming years. Currently, there are no effective medications to treat it. Due to limited treatment options, patients often resort to supplements, such as collagen hydrolysates...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Medicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2305-6320/10/9/50 |
| _version_ | 1797578889258598400 |
|---|---|
| author | Christina E. Larder Michèle M. Iskandar Stan Kubow |
| author_facet | Christina E. Larder Michèle M. Iskandar Stan Kubow |
| author_sort | Christina E. Larder |
| collection | DOAJ |
| description | Osteoarthritis (OA) is the most common joint disorder, with a social and financial burden that is expected to increase in the coming years. Currently, there are no effective medications to treat it. Due to limited treatment options, patients often resort to supplements, such as collagen hydrolysates (CHs). CHs are products with low molecular weight (MW) peptides, often between 3 and 6 kDa, and are a result of industrialized processed collagen. Collagen extraction is often a by-product of the meat industry, with the main source for collagen-based products being bovine, although it can also be obtained from porcine and piscine sources. CHs have demonstrated positive results in clinical trials related to joint health, such as decreased joint pain, increased mobility, and structural joint improvements. The bioactivity of CHs is primarily attributed to their bioactive peptide (BAP) content. However, there are significant knowledge gaps regarding the digestion, bioavailability, and bioactivity of CH-derived BAPs, and how different CH products compare in that regard. The present review discusses CHs and their BAP content as potential treatments for OA. |
| first_indexed | 2024-03-10T22:29:07Z |
| format | Article |
| id | doaj.art-80eaf4392e094f8387a80d3871e580cc |
| institution | Directory Open Access Journal |
| issn | 2305-6320 |
| language | English |
| last_indexed | 2024-03-10T22:29:07Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicines |
| spelling | doaj.art-80eaf4392e094f8387a80d3871e580cc2023-11-19T11:53:35ZengMDPI AGMedicines2305-63202023-09-011095010.3390/medicines10090050Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of OsteoarthritisChristina E. Larder0Michèle M. Iskandar1Stan Kubow2School of Human Nutrition, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, CanadaSchool of Human Nutrition, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, CanadaSchool of Human Nutrition, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, CanadaOsteoarthritis (OA) is the most common joint disorder, with a social and financial burden that is expected to increase in the coming years. Currently, there are no effective medications to treat it. Due to limited treatment options, patients often resort to supplements, such as collagen hydrolysates (CHs). CHs are products with low molecular weight (MW) peptides, often between 3 and 6 kDa, and are a result of industrialized processed collagen. Collagen extraction is often a by-product of the meat industry, with the main source for collagen-based products being bovine, although it can also be obtained from porcine and piscine sources. CHs have demonstrated positive results in clinical trials related to joint health, such as decreased joint pain, increased mobility, and structural joint improvements. The bioactivity of CHs is primarily attributed to their bioactive peptide (BAP) content. However, there are significant knowledge gaps regarding the digestion, bioavailability, and bioactivity of CH-derived BAPs, and how different CH products compare in that regard. The present review discusses CHs and their BAP content as potential treatments for OA.https://www.mdpi.com/2305-6320/10/9/50peptidecollagen hydrolysateosteoarthritisbioavailabilityhuman healthamino acids |
| spellingShingle | Christina E. Larder Michèle M. Iskandar Stan Kubow Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis Medicines peptide collagen hydrolysate osteoarthritis bioavailability human health amino acids |
| title | Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis |
| title_full | Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis |
| title_fullStr | Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis |
| title_full_unstemmed | Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis |
| title_short | Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis |
| title_sort | collagen hydrolysates a source of bioactive peptides derived from food sources for the treatment of osteoarthritis |
| topic | peptide collagen hydrolysate osteoarthritis bioavailability human health amino acids |
| url | https://www.mdpi.com/2305-6320/10/9/50 |
| work_keys_str_mv | AT christinaelarder collagenhydrolysatesasourceofbioactivepeptidesderivedfromfoodsourcesforthetreatmentofosteoarthritis AT michelemiskandar collagenhydrolysatesasourceofbioactivepeptidesderivedfromfoodsourcesforthetreatmentofosteoarthritis AT stankubow collagenhydrolysatesasourceofbioactivepeptidesderivedfromfoodsourcesforthetreatmentofosteoarthritis |